SLC5A2 and diabetes mellitus: Considering that ertugliflozin is the most potent rapidly absorbed drug and that dapagliflozin is excreted most slowly by the kidneys among the three SGLT2 inhibitors, our findings further demonstrate a positive relationship between rapid drug action and higher risk of adverse events with SGLT2 inhibitors in patients with DM [51, 52].